Investors focused on the Medical space have likely heard of BioTelemetry (BEAT Quick QuoteBEAT - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

BioTelemetry is one of 838 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. BEAT is currently sporting a Zacks Rank of #1 (Strong Buy).

Within the past quarter, the Zacks Consensus Estimate for BEAT's full-year earnings has moved 19.34% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Based on the latest available data, BEAT has gained about 92.51% so far this year. Meanwhile, stocks in the Medical group have lost about 5.70% on average. This shows that BioTelemetry is outperforming its peers so far this year.

To break things down more, BEAT belongs to the Medical Services industry, a group that includes 33 individual companies and currently sits at #82 in the Zacks Industry Rank. This group has gained an average of 11.89% so far this year, so BEAT is performing better in this area.

BEAT will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.